PDA

View Full Version : Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit

News
12-04-2015, 06:30 AM
No proof of positive effects, more treatment discontinuations due to side effects.Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications.

More... (http://www.medicalnewstoday.com/releases/303593.php)